Radioligand therapy (#RLT) could be a true paradigm shift in oncology, a potential new pillar of cancer care. However, healthcare system (HCS) readiness for widespread adoption of RLT is behind the speed of innovation. Novartis is partnering with industry and regional HCSs to build capacity for RLT, supporting policies and accelerating referral and funding pathways. Join us at #ESMO2024 where we are leading a panel discussion with industry experts to discuss how we can work together to shape a future where patients with advanced cancers can live better.
소개
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki
- 웹사이트
-
http://www.novartis.com
Novartis 외부 링크
- 업계
- 제약
- 회사 규모
- 직원 10,001명 이상
- 본사
- Baselstadt Basel
- 유형
- 상장기업
- 전문 분야
- Cardiovascular, Immunology, Neuroscience, Solid Tumors, Hematology, Chemistry, xRNA, Radioligand 및 Gene and cell therapy
위치
Novartis 직원
-
Guy Dickinson
Figuring out #FutureOfWork: GenerativeAi + Employee Experience + Behavioural Design + Capability Building + Digital Skills
-
David Yee
Head Portfolio Systems, Portfolio Strategy & Analytics, Strategy & Growth at Novartis
-
Rodolfo Garcia de Alba Cassaigne
Regional Category Procurement Director, US Marketing Agencies
-
Kelley Dallas Priddy, M.S.
Medical Sales Specialist | Award Winner | Drives Sales Performance Through Analytics & Business Planning
업데이트
-
Cancer is a heterogeneous disease with nearly 20 million people diagnosed in 2022 alone. At Novartis, we are on a mission to develop innovative therapies that improve the future of cancer care. Our broad oncology portfolio addresses pressing unmet needs in a range of advanced cancers, aiming to improve outcomes and enhance quality of life (#QoL) for patients and their loved ones. Learn more about our ongoing efforts in oncology: https://lnkd.in/ggv5umCv
-
As we increase our radioligand therapy (RLT) manufacturing footprint, we are intentionally creating space for continued innovation and growth, driven by the opportunities these advancements may present for patients worldwide. #ReimagineMedicine
Today we announced the construction of two new radioligand therapy (RLT) manufacturing facilities, one of which will produce critical isotopes necessary to create these medicines. As the leader in RLT development and delivery, we remain committed to pioneering RLT science and broadening manufacturing capabilities to support the growing demand for this novel approach to cancer care.
-
At Novartis, we envision a world where preventable cardiovascular deaths are no longer part of our lives. The City Heartbeat Index is being launched today by the World Heart Federation. The Index assessed efforts to understand, prevent and address CVD in 50 cities worldwide, serving as a benchmark for cities on their efforts to protect people’s health. Over half of the world’s population live in cities making this a major step forward to support the development of targeted public health interventions We’re proud to have commissioned the study, independently conducted by Economist Impact. It is by working together, with patients, healthcare professionals, and organizations around the world, that we can have the biggest impact with these learnings. Gain an insight into the key takeaways here and then explore how your city scored: https://lnkd.in/euT4WzFF *Correction: New York = 4/50, Berlin = 5/50
-
Our Q2 performance reflects the continued strong momentum of Novartis. Across the company our teams demonstrated strong commercial execution both in the US and internationally. We also advanced our pipeline, completing new FDA submissions and executing multiple deals to expand our pipeline in RLT and prostate cancer. It’s a great time to be at Novartis as we remain on track for the future. https://lnkd.in/gNdZv2pP #NVSQ224
-
Chronic myeloid leukemia (CML) is a type of cancer that affects the blood and bone marrow, where blood cells are made. Recognizing the symptoms of CML is crucial for early detection. These can include fatigue, weight loss, fever, and an enlarged spleen causing discomfort on the left side of the abdomen. Taking proactive steps with your healthcare provider for regular check-ups and monitoring can be beneficial, leading to better disease management and improved quality of life (#QoL). Learn more about CML and its management here: https://lnkd.in/gVRjQiAy
Understanding and managing CML
-
At #EHA24, we are proud to present data from our Phase III ASC4FIRST trial for patients with newly diagnosed chronic myeloid leukemia (#CML). CML is a type of cancer that develops in the blood-forming cells of the bone marrow. Despite 25+ years of innovation in CML, unmet needs still exist as newly diagnosed patients may fail to meet molecular response goals or discontinue or change treatments due to intolerance. Learn more about Novartis commitment to fighting blood cancers: https://lnkd.in/gvzPZJiQ
-
Paroxysmal nocturnal hemoglobinuria (PNH) is a debilitating blood disorder which causes a range of life-limiting symptoms for those affected. We spoke to the Aplastic Anemia and MDS International Foundation (AAMDSIF) to highlight the importance of providing support for patients living with rare diseases Click the link to learn more about AAMDSIF and the strides they are making to improve life for people living with PNH: https://lnkd.in/gZUvmp-T
-
We are proud to share that our study investigating #radioligandtherapy has been selected as Abstract of the Year by Society of Nuclear Medicine and Molecular Imaging (SNMMI), reinforcing its potential for patients in need. #ReimagineMedicine #SNMMI24
-
At Novartis, our long-standing commitment to patients living with chronic myeloid leukemia (CML) spans more than two decades, marked by breakthroughs that have helped turn what was once a life-limiting condition into a chronic one for many. Yet, there's more ground to cover. Despite advancements, many patients still face hurdles such as lower response rates, treatment resistance, and intolerance, and have poor quality of life. That’s why we’re committed to continuing to pioneer targeted treatments for CML, and ensuring every patient has access to innovative medicines. Learn more here: https://lnkd.in/gadSYVJg
Pioneering solutions for patients with CML